Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells

We investigated the interaction of liposomes surface-modified with soybean-derived sterylglucoside (SG) (SG-liposomes) with HepG2 cells in the point of involvement of asialoglycoprotein receptor (ASGP-R) mediated endocytosis and examined the efficiency of SG-liposomes as drug carriers using 1,1′-dio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of controlled release 2001-08, Vol.75 (3), p.381-389
Hauptverfasser: Maitani, Yoshie, Kawano, Kumi, Yamada, Kazuyo, Nagai, Tsuneji, Takayama, Kozo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 389
container_issue 3
container_start_page 381
container_title Journal of controlled release
container_volume 75
creator Maitani, Yoshie
Kawano, Kumi
Yamada, Kazuyo
Nagai, Tsuneji
Takayama, Kozo
description We investigated the interaction of liposomes surface-modified with soybean-derived sterylglucoside (SG) (SG-liposomes) with HepG2 cells in the point of involvement of asialoglycoprotein receptor (ASGP-R) mediated endocytosis and examined the efficiency of SG-liposomes as drug carriers using 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI) as a maker of liposome, carboxylated polystyrene microspheres (Fluoresbrite) as a model drug not taken up in cells and doxorubicin (DXR). SG-liposomes were composed of dipalmitoylphosphatidylcholine (DPPC), cholesterol (Ch) and SG (DPPC/Ch/SG=6:3:1, molar ratio) and DiI, Fluoresbrite and DXR were entrapped in SG-liposomes, respectively. Each SG-liposome was incubated with HepG2 cells at 4 or 37°C, and co-incubated with asialofetuin (AF) as a competitor of ASGP-R. The association of DiI, Fluoresbrite or DXR entrapped in SG-liposomes with HepG2 cells at 37°C was significantly higher than that in liposomes containing no SG. That of DiI and Fluoresbrite was reduced significantly by the incubation with AF, but that of DXR was not affected. These findings suggest that Fluoresbrite behaves like the lipid component of SG-liposomes, but DXR in SG-liposomes does not behave similar to the lipid component of SG-liposomes, thus, its drug behavior released from liposomes may be due to its physicochemical properties. SG-liposomes are potentially useful drug carriers to the liver, because the glucose residue may work as a kind of ligand for ASGP-R.
doi_str_mv 10.1016/S0168-3659(01)00411-4
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17905721</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365901004114</els_id><sourcerecordid>17905721</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-a5bdd281827e908b1840a11550c31e54078f1d60e02e5584c6e835b2b7434d343</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EokvhJ4B8QAgOKZ7Y3jgnhKp-IFXqAThbjj1ZjJJ48SSL8u_Jfqj01stYGj1-Z_QMY29BXICA9efvSzGFXOv6o4BPQiiAQj1jKzCVLFRd6-ds9YCcsVdEv4UQWqrqJTsDUKaWpVqx-apto484-Jmnlndxmyj1SJym3DqPRZ9CbCMG_jeOvziluUE3FAFz3C1NGjHP3aabfKIYkDvibgnZYeajyxsc47Dh3uUcl04c-C1ub0rusevoNXvRuo7wzek9Zz-vr35c3hZ39zffLr_eFV6VMBZONyGUBkxZYS1MA0YJB6C18BJQK1GZFsJaoChRa6P8Go3UTdlUSqoglTxnH46525z-TEij7SPtN3ADpoksVLXQVQkLqI-gz4koY2u3OfYuzxaE3Tu3B-d2L9QKsAfndj_g3WnA1PQY_v86SV6A9yfAkXddm93gIz1KN9LU9YJ9OWK42NgtwiwdDoMhZvSjDSk-sck_u9-eOQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17905721</pqid></control><display><type>article</type><title>Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Maitani, Yoshie ; Kawano, Kumi ; Yamada, Kazuyo ; Nagai, Tsuneji ; Takayama, Kozo</creator><creatorcontrib>Maitani, Yoshie ; Kawano, Kumi ; Yamada, Kazuyo ; Nagai, Tsuneji ; Takayama, Kozo</creatorcontrib><description>We investigated the interaction of liposomes surface-modified with soybean-derived sterylglucoside (SG) (SG-liposomes) with HepG2 cells in the point of involvement of asialoglycoprotein receptor (ASGP-R) mediated endocytosis and examined the efficiency of SG-liposomes as drug carriers using 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI) as a maker of liposome, carboxylated polystyrene microspheres (Fluoresbrite) as a model drug not taken up in cells and doxorubicin (DXR). SG-liposomes were composed of dipalmitoylphosphatidylcholine (DPPC), cholesterol (Ch) and SG (DPPC/Ch/SG=6:3:1, molar ratio) and DiI, Fluoresbrite and DXR were entrapped in SG-liposomes, respectively. Each SG-liposome was incubated with HepG2 cells at 4 or 37°C, and co-incubated with asialofetuin (AF) as a competitor of ASGP-R. The association of DiI, Fluoresbrite or DXR entrapped in SG-liposomes with HepG2 cells at 37°C was significantly higher than that in liposomes containing no SG. That of DiI and Fluoresbrite was reduced significantly by the incubation with AF, but that of DXR was not affected. These findings suggest that Fluoresbrite behaves like the lipid component of SG-liposomes, but DXR in SG-liposomes does not behave similar to the lipid component of SG-liposomes, thus, its drug behavior released from liposomes may be due to its physicochemical properties. SG-liposomes are potentially useful drug carriers to the liver, because the glucose residue may work as a kind of ligand for ASGP-R.</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/S0168-3659(01)00411-4</identifier><identifier>PMID: 11489324</identifier><identifier>CODEN: JCREEC</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>alpha-Fetoproteins - pharmacology ; Asialoglycoprotein Receptor ; Asialoglycoproteins - pharmacology ; Biological and medical sciences ; Cholestenes - administration &amp; dosage ; Doxorubicin - administration &amp; dosage ; Drug Carriers ; Endocytosis ; Fetuins ; General pharmacology ; Glycine max ; HepG2 cells ; Humans ; Liposome ; Liposomes ; Liver - metabolism ; Liver targeting ; Medical sciences ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Receptors, Cell Surface - physiology ; Serum Albumin, Bovine - pharmacokinetics ; Soybean-derived sterylglucoside ; sterylglucoside ; Tumor Cells, Cultured</subject><ispartof>Journal of controlled release, 2001-08, Vol.75 (3), p.381-389</ispartof><rights>2001 Elsevier Science B.V.</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-a5bdd281827e908b1840a11550c31e54078f1d60e02e5584c6e835b2b7434d343</citedby><cites>FETCH-LOGICAL-c421t-a5bdd281827e908b1840a11550c31e54078f1d60e02e5584c6e835b2b7434d343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168365901004114$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1083899$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11489324$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maitani, Yoshie</creatorcontrib><creatorcontrib>Kawano, Kumi</creatorcontrib><creatorcontrib>Yamada, Kazuyo</creatorcontrib><creatorcontrib>Nagai, Tsuneji</creatorcontrib><creatorcontrib>Takayama, Kozo</creatorcontrib><title>Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>We investigated the interaction of liposomes surface-modified with soybean-derived sterylglucoside (SG) (SG-liposomes) with HepG2 cells in the point of involvement of asialoglycoprotein receptor (ASGP-R) mediated endocytosis and examined the efficiency of SG-liposomes as drug carriers using 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI) as a maker of liposome, carboxylated polystyrene microspheres (Fluoresbrite) as a model drug not taken up in cells and doxorubicin (DXR). SG-liposomes were composed of dipalmitoylphosphatidylcholine (DPPC), cholesterol (Ch) and SG (DPPC/Ch/SG=6:3:1, molar ratio) and DiI, Fluoresbrite and DXR were entrapped in SG-liposomes, respectively. Each SG-liposome was incubated with HepG2 cells at 4 or 37°C, and co-incubated with asialofetuin (AF) as a competitor of ASGP-R. The association of DiI, Fluoresbrite or DXR entrapped in SG-liposomes with HepG2 cells at 37°C was significantly higher than that in liposomes containing no SG. That of DiI and Fluoresbrite was reduced significantly by the incubation with AF, but that of DXR was not affected. These findings suggest that Fluoresbrite behaves like the lipid component of SG-liposomes, but DXR in SG-liposomes does not behave similar to the lipid component of SG-liposomes, thus, its drug behavior released from liposomes may be due to its physicochemical properties. SG-liposomes are potentially useful drug carriers to the liver, because the glucose residue may work as a kind of ligand for ASGP-R.</description><subject>alpha-Fetoproteins - pharmacology</subject><subject>Asialoglycoprotein Receptor</subject><subject>Asialoglycoproteins - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cholestenes - administration &amp; dosage</subject><subject>Doxorubicin - administration &amp; dosage</subject><subject>Drug Carriers</subject><subject>Endocytosis</subject><subject>Fetuins</subject><subject>General pharmacology</subject><subject>Glycine max</subject><subject>HepG2 cells</subject><subject>Humans</subject><subject>Liposome</subject><subject>Liposomes</subject><subject>Liver - metabolism</subject><subject>Liver targeting</subject><subject>Medical sciences</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, Cell Surface - physiology</subject><subject>Serum Albumin, Bovine - pharmacokinetics</subject><subject>Soybean-derived sterylglucoside</subject><subject>sterylglucoside</subject><subject>Tumor Cells, Cultured</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhi0EokvhJ4B8QAgOKZ7Y3jgnhKp-IFXqAThbjj1ZjJJ48SSL8u_Jfqj01stYGj1-Z_QMY29BXICA9efvSzGFXOv6o4BPQiiAQj1jKzCVLFRd6-ds9YCcsVdEv4UQWqrqJTsDUKaWpVqx-apto484-Jmnlndxmyj1SJym3DqPRZ9CbCMG_jeOvziluUE3FAFz3C1NGjHP3aabfKIYkDvibgnZYeajyxsc47Dh3uUcl04c-C1ub0rusevoNXvRuo7wzek9Zz-vr35c3hZ39zffLr_eFV6VMBZONyGUBkxZYS1MA0YJB6C18BJQK1GZFsJaoChRa6P8Go3UTdlUSqoglTxnH46525z-TEij7SPtN3ADpoksVLXQVQkLqI-gz4koY2u3OfYuzxaE3Tu3B-d2L9QKsAfndj_g3WnA1PQY_v86SV6A9yfAkXddm93gIz1KN9LU9YJ9OWK42NgtwiwdDoMhZvSjDSk-sck_u9-eOQ</recordid><startdate>20010810</startdate><enddate>20010810</enddate><creator>Maitani, Yoshie</creator><creator>Kawano, Kumi</creator><creator>Yamada, Kazuyo</creator><creator>Nagai, Tsuneji</creator><creator>Takayama, Kozo</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20010810</creationdate><title>Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells</title><author>Maitani, Yoshie ; Kawano, Kumi ; Yamada, Kazuyo ; Nagai, Tsuneji ; Takayama, Kozo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-a5bdd281827e908b1840a11550c31e54078f1d60e02e5584c6e835b2b7434d343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>alpha-Fetoproteins - pharmacology</topic><topic>Asialoglycoprotein Receptor</topic><topic>Asialoglycoproteins - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cholestenes - administration &amp; dosage</topic><topic>Doxorubicin - administration &amp; dosage</topic><topic>Drug Carriers</topic><topic>Endocytosis</topic><topic>Fetuins</topic><topic>General pharmacology</topic><topic>Glycine max</topic><topic>HepG2 cells</topic><topic>Humans</topic><topic>Liposome</topic><topic>Liposomes</topic><topic>Liver - metabolism</topic><topic>Liver targeting</topic><topic>Medical sciences</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, Cell Surface - physiology</topic><topic>Serum Albumin, Bovine - pharmacokinetics</topic><topic>Soybean-derived sterylglucoside</topic><topic>sterylglucoside</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maitani, Yoshie</creatorcontrib><creatorcontrib>Kawano, Kumi</creatorcontrib><creatorcontrib>Yamada, Kazuyo</creatorcontrib><creatorcontrib>Nagai, Tsuneji</creatorcontrib><creatorcontrib>Takayama, Kozo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maitani, Yoshie</au><au>Kawano, Kumi</au><au>Yamada, Kazuyo</au><au>Nagai, Tsuneji</au><au>Takayama, Kozo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2001-08-10</date><risdate>2001</risdate><volume>75</volume><issue>3</issue><spage>381</spage><epage>389</epage><pages>381-389</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><coden>JCREEC</coden><abstract>We investigated the interaction of liposomes surface-modified with soybean-derived sterylglucoside (SG) (SG-liposomes) with HepG2 cells in the point of involvement of asialoglycoprotein receptor (ASGP-R) mediated endocytosis and examined the efficiency of SG-liposomes as drug carriers using 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI) as a maker of liposome, carboxylated polystyrene microspheres (Fluoresbrite) as a model drug not taken up in cells and doxorubicin (DXR). SG-liposomes were composed of dipalmitoylphosphatidylcholine (DPPC), cholesterol (Ch) and SG (DPPC/Ch/SG=6:3:1, molar ratio) and DiI, Fluoresbrite and DXR were entrapped in SG-liposomes, respectively. Each SG-liposome was incubated with HepG2 cells at 4 or 37°C, and co-incubated with asialofetuin (AF) as a competitor of ASGP-R. The association of DiI, Fluoresbrite or DXR entrapped in SG-liposomes with HepG2 cells at 37°C was significantly higher than that in liposomes containing no SG. That of DiI and Fluoresbrite was reduced significantly by the incubation with AF, but that of DXR was not affected. These findings suggest that Fluoresbrite behaves like the lipid component of SG-liposomes, but DXR in SG-liposomes does not behave similar to the lipid component of SG-liposomes, thus, its drug behavior released from liposomes may be due to its physicochemical properties. SG-liposomes are potentially useful drug carriers to the liver, because the glucose residue may work as a kind of ligand for ASGP-R.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>11489324</pmid><doi>10.1016/S0168-3659(01)00411-4</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0168-3659
ispartof Journal of controlled release, 2001-08, Vol.75 (3), p.381-389
issn 0168-3659
1873-4995
language eng
recordid cdi_proquest_miscellaneous_17905721
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects alpha-Fetoproteins - pharmacology
Asialoglycoprotein Receptor
Asialoglycoproteins - pharmacology
Biological and medical sciences
Cholestenes - administration & dosage
Doxorubicin - administration & dosage
Drug Carriers
Endocytosis
Fetuins
General pharmacology
Glycine max
HepG2 cells
Humans
Liposome
Liposomes
Liver - metabolism
Liver targeting
Medical sciences
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Receptors, Cell Surface - physiology
Serum Albumin, Bovine - pharmacokinetics
Soybean-derived sterylglucoside
sterylglucoside
Tumor Cells, Cultured
title Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T18%3A29%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficiency%20of%20liposomes%20surface-modified%20with%20soybean-derived%20sterylglucoside%20as%20a%20liver%20targeting%20carrier%20in%20HepG2%20cells&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Maitani,%20Yoshie&rft.date=2001-08-10&rft.volume=75&rft.issue=3&rft.spage=381&rft.epage=389&rft.pages=381-389&rft.issn=0168-3659&rft.eissn=1873-4995&rft.coden=JCREEC&rft_id=info:doi/10.1016/S0168-3659(01)00411-4&rft_dat=%3Cproquest_cross%3E17905721%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17905721&rft_id=info:pmid/11489324&rft_els_id=S0168365901004114&rfr_iscdi=true